News, reviews and podcasts from annual scientific meetings and symposiums around the world.
Results from the OlympiA clinical trial shows that olaparib reduces breast cancer recurrence by 42%…
Immunotherapy after surgery significantly improved disease-free survival (DFS) for patients with the most common type…
The addition of the immunotherapy agent toripalimab to standard first-line chemotherapy significantly delayed disease progression…
Nearly three-quarters of breast cancer patients (73%) report using at least one type of complementary…
In a presentation of real-world data, researchers from Fox Chase Cancer Center, USA, have concluded…
In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma,…
In a breakthrough which could extend to the treatment of other cancers, a new immune…
“Immunotherapy has transformed the outlook for patients with advanced melanoma. The success seen in this…
“For the first time, we are seeing that an immunotherapy is effective when used to…
Many early-stage patients with bulky classic Hodgkin lymphoma (cHL) can avoid radiotherapy treatment and still…